[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

• US 7,160,888 B2
• Filed: 07/28/2004
• Issued: 01/09/2007
• Est. Priority Date: 08/22/2003
• Status: Expired due to Fees

• Current Assignee: Warner-Lambert Company LLC (Pfizer Inc.)
• Original Assignee: Warner-Lambert Company LLC (Pfizer Inc.)
• Inventors: Repine, Joseph Thomas, Johnson, Douglas S., White, Andrew David
• Primary Examiner(s): BERNHARDT, EMILY A
• Application Number:
  US10/900,210
• Publication Number:
  US 20050043309A1
• Time in Patent Office: 895 Days
• Field of Search: 544/362, 514/253.04
• US Class Current: 514/253.04
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 25/32 Alcohol-abuse
• CPC Class Codes: A61P 25/34 Tobacco-abuse
• CPC Class Codes: A61P 25/36 Opioid-abuse
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 471/04 Ortho-condensed systems

Abstract

This invention relates to compounds of the formula 1

wherein G, D, A, Z, Q, X, Y, R¹, and R⁴ through R⁷ are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

Claims

1. The compound 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one, or a pharmaceutically acceptable salt thereof.

2. The pharmaceutically acceptable salt of the compound 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one according to claim 1, which is a phosphoric acid addition salt.

4. A pharmaceutical composition comprising a pharmaceutically acceptable salt of the compound 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one according to claim 2, and a pharmaceutically acceptable carrier.

3. A pharmaceutical composition comprising the compound 7-[4-(4-napthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5. A method of treating schizophrenia or bipolar disorder in a human in need thereof, comprising administering to the human an effective amount of the compound 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one, or a pharmaceutically acceptable salt thereof.

6. The method according to claim 5, comprising administering to the human an effective amount of a pharmaceutically acceptable salt of the compound 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1H-[1,8]naphthyridin-2-one.

7. The compound 7-{4-[4-(8-fluoro-naphthalen-1-yl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-[1,8]naphthyridin-2-one, or a pharmaceutically acceptable salt thereof.

8. The pharmaceutically acceptable salt of the compound 7-{4-[4-(8-fluoro-naphthalen-1-yl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-[1,8]naphthyridin-2-one according to claim 7, which is a phosphoric acid addition salt.

10. A pharmaceutical composition comprising a pharmaceutically acceptable salt of the compound 7-{4-[4-(8-fluoro-naphthalen-1-yl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-[1,8]naphthyridin-2-one according to claim 8, and a pharmaceutically acceptable carrier.

9. A pharmaceutical composition comprising the compound 7-{4-[4-(8-fluoro-naphthalen-1-yl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-[1,8]naphthyridin-2-one, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

11. A method of treating schizophrenia or bipolar disorder in a human in need thereof, comprising administering to the human an effective amount of the compound 7-{4-[4-(8-fluoro-naphthalen-1-yl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-[1,8]naphthyridin-2-one, or a pharmaceutically acceptable salt thereof.

12. The method according to claim 11, comprising administering to the human an effective amount of a pharmaceutically acceptable salt of the compound 7-{4-[4-(8-fluoro-naphthalen-1-yl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-[1,8]naphthyridin-2-one.